{
  "ticker": "LLY",
  "target_date": "2025-07-08",
  "actual_date": "2025-07-08",
  "collected_at": "2025-12-08T11:59:14.269837",
  "price": {
    "open": 772.02,
    "high": 789.79,
    "low": 765.99,
    "close": 774.8177490234375,
    "volume": 3301800,
    "change_1d_pct": 0.62,
    "change_7d_pct": -2.2,
    "change_30d_pct": 8.73
  },
  "technicals": {
    "rsi_14": 37.74,
    "sma_20": 784.37,
    "sma_50": 773.39,
    "macd": 2.059,
    "macd_signal": 3.922,
    "macd_histogram": -1.863,
    "bb_upper": 816.37,
    "bb_lower": 752.38,
    "price_vs_sma20_pct": -1.22,
    "price_vs_sma50_pct": 0.18,
    "volume_ratio": 1.07
  },
  "fundamentals": {
    "market_cap": 893471490048,
    "pe_ratio": 48.83243,
    "forward_pe": 43.98367,
    "price_to_book": 37.525223,
    "price_to_sales": 15.036595,
    "profit_margin": 30.99,
    "operating_margin": 48.29,
    "roe": 96.47,
    "roa": 17.6,
    "revenue_growth": 53.9,
    "earnings_growth": 480.4,
    "debt_to_equity": 178.516,
    "current_ratio": 1.546,
    "quick_ratio": 0.724,
    "dividend_yield": 59.0,
    "fifty_two_week_high": 1111.99,
    "fifty_two_week_low": 623.78,
    "fifty_day_avg": 911.5326,
    "two_hundred_day_avg": 811.9354,
    "analyst_target": 1056.7045,
    "analyst_recommendation": "buy",
    "num_analysts": 27,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -10.37,
    "pct_from_52w_low": 59.78
  },
  "macro": {
    "spy": {
      "price": 618.62,
      "change_1d_pct": -0.05,
      "change_7d_pct": 0.88
    },
    "vix": {
      "level": 16.81,
      "signal": "NORMAL"
    },
    "treasury_10y": {
      "yield_pct": 4.41
    },
    "dollar_index": {
      "level": 97.51
    },
    "gold": {
      "price": 3307.0
    },
    "regime": "BULL_NORMAL"
  },
  "news": [
    {
      "headline": "Regeneron\u2019s Blockbuster Dupixent Faces a New Rival",
      "source": "Yahoo",
      "datetime": 1752003060,
      "summary": "The franchise drug for autoimmune disorders such as dermatitis could face a challenger: A candidate from Apogee Therapeutics.",
      "url": "https://finnhub.io/api/news?id=72ab8a0ed65ba42ffcf3d1414cbeeb86240470ea9c437ed7c9a9602e5fd18121"
    },
    {
      "headline": "Trump Says He\u2019ll Set 50% Copper Tariff, Wait Year on Drug Levies",
      "source": "Yahoo",
      "datetime": 1751998713,
      "summary": "(Bloomberg) -- President Donald Trump said he planned to implement a 50% duty on copper imports as part of a set of looming sectoral tariffs, while also indicating he could offer pharmaceutical manufacturers at least a year before applying a crippling 200% tariff on their foreign-made products.Most ",
      "url": "https://finnhub.io/api/news?id=1fccd845f4c89020e26d492afff3027881ba9c88390597dc1d1652f6a7556f03"
    },
    {
      "headline": "Trump says pharma tariffs may reach 200%, hitting in 12 to 18 months",
      "source": "MarketWatch",
      "datetime": 1751981508,
      "summary": "Trump says pharma tariffs may reach 200%, hitting in 12 to 18 months",
      "url": "https://finnhub.io/api/news?id=3077807c43b78e2edb81b8f062b911184ce713eb3b6e888f3ad03d1dd34750d6"
    },
    {
      "headline": "How Will Skyrizi and Rinvoq Sales Aid AbbVie's Upcoming Q2 Results?",
      "source": "Yahoo",
      "datetime": 1751977620,
      "summary": "ABBV leans on Skyrizi and Rinvoq sales strength to offset Humira's decline ahead of its Q2 earnings report.",
      "url": "https://finnhub.io/api/news?id=a18c12cd77ddee6772eeda08f133bcb8c233bd69bdcc839a042f8df8b92a629b"
    },
    {
      "headline": "Schizophrenia Market Research and Forecast Report 2025-2034 | Emerging Therapies and Genetic Research Drive Growth with Bristol Myers Squibb, AstraZeneca, and Eli Lilly Leading",
      "source": "Yahoo",
      "datetime": 1751975340,
      "summary": "The schizophrenia market is projected to grow from USD 7.78 billion in 2024 to USD 13.67 billion by 2034, with a CAGR of 5.80%. Key growth drivers include rising schizophrenia prevalence, increased use of long-acting injectable antipsychotics, and advances in genetic and digital therapeutics. The U.",
      "url": "https://finnhub.io/api/news?id=c10c9f7ec1a928a4f3710c0f4cce26ca1b02faf7c2e177ae419202b4780a48d7"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "4",
      "date": "2025-06-17",
      "description": "xslF345X05/wk-form4_1750199300.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000176/xslF345X05/wk-form4_1750199300.xml"
    },
    {
      "form": "4",
      "date": "2025-06-17",
      "description": "xslF345X05/wk-form4_1750199159.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000174/xslF345X05/wk-form4_1750199159.xml"
    },
    {
      "form": "4",
      "date": "2025-06-17",
      "description": "xslF345X05/wk-form4_1750198988.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000172/xslF345X05/wk-form4_1750198988.xml"
    },
    {
      "form": "4",
      "date": "2025-06-17",
      "description": "xslF345X05/wk-form4_1750198711.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000170/xslF345X05/wk-form4_1750198711.xml"
    },
    {
      "form": "4",
      "date": "2025-06-17",
      "description": "xslF345X05/wk-form4_1750198504.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000168/xslF345X05/wk-form4_1750198504.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}